The use of Deoxycholic Acid for the Clinical Reduction of Excess Submental Fat in Indian Patients
Shome, D.; Khare, S.; Kapoor, R.
Journal of Drugs in Dermatology Jdd 18(3): 266-272
2019
ISSN/ISBN: 1545-9616 PMID: 30909331 Document Number: 17748
Copy: The injectable adipocytolytic drug deoxycholic acid (DCA) is the first pharmacological intervention approved for the reduction of submental fat (SMF) and offers an alternative to invasive measures to improve the submental profile and the cervico-mental angle. DCA injection (ATX-101, Kybella [United States], Belkyra [Canada]; Kythera Biopharmaceuticals, Inc., Westlake Village, CA, acquired by Allergan, Inc.), are proprietary formulations of synthetically derived DCA that is FDA approved for improvement in the appearance of moderate to severe convexity or fullness associated with SMF.
Document emailed within 1 workday
